Question 1

What is ImmunoMAPs Intelligence Pro?

Accepted Answer

It is the clinical-development intelligence layer of ImmunoMAPs, focused on immuno-oncology therapies, targets, cancer indications, trials, FDA/EMA regulatory evidence, biomarkers, publications and immune-related safety.

Question 2

What is the Therapeutic Evidence Atlas?

Accepted Answer

The Therapeutic Evidence Atlas is the graph-ready evidence model that connects therapies to targets, mechanisms, diseases, biomarkers, trials, outcomes, regulatory indications, safety evidence and ImmunoMAPs analytical outputs.

Question 3

How does Intelligence Pro connect to ImmunoMAPs analytics?

Accepted Answer

Users can move from an intelligence record or disease landscape into the CAR-T Cell Suite, Antibody Innovator Suite or ICI Development Suite for deeper downstream analysis.

Question 4

How are clinical-study matches ranked?

Accepted Answer

Search relevance explains where query terms matched. Comparable-study ranking is a separate, missingness-aware assessment across disease, modality, phase, design, population, endpoints and geography, with observed coverage shown beside the score.

Question 5

Are ICI, CAR-T and antibody cohort counts additive?

Accepted Answer

No. A combination or multimodal study may carry more than one governed immuno-oncology classification, so the suite cohort counts overlap and must not be summed.

Question 6

Does ImmunoMAPs treat a completed clinical trial as successful?

Accepted Answer

No. Study recruitment status and trial outcome are separate. A COMPLETED study has finished accrual, not necessarily met its endpoint. Positive, negative or mixed result assertions require source-supported evidence.

Question 7

Which data sources does the Therapeutic Evidence Atlas ingest?

Accepted Answer

Official sources including ClinicalTrials.gov study records, FDA and EMA regulatory evidence, PubMed literature and pharmacovigilance reporting. Each source is stored as an immutable snapshot with a SHA-256 checksum, so every record stays traceable to its origin.

Question 8

How does Intelligence Pro handle immune-related adverse event safety data?

Accepted Answer

Safety evidence is kept in separate layers that are never merged: trial aggregate counts with a denominator, pharmacovigilance disproportionality signals within one report universe, regulatory label assertions, and patient-level events. Spontaneous reporting is never presented as incidence or as proof of causality.